文献检索
文档翻译
深度研究
Zotero 插件
邀请有礼
套餐&价格
历史记录
Suppr
超能文献
应用&插件
文献AI研究员
20分钟写一篇综述，助力文献阅读效率提升50倍。
立即体验
用中文搜PubMed
大模型驱动的PubMed中文搜索引擎
马上搜索
文档翻译
学术文献翻译模型，支持多种主流文档格式。
立即体验
应用&插件
Zotero 插件
浏览器插件
Mac 客户端
Windows 客户端
微信小程序
定价
高级版会员
购买积分包
购买API积分包
服务
文献检索
文档翻译
深度研究
API 文档
关于我们
关于 Suppr
公司介绍
联系我们
用户协议
隐私条款
关注我们
Suppr 超能文献
核心技术专利：
CN118964589B
侵权必究
粤ICP备2023148730 号-1
Suppr @ 2025
相似文献
1
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management.
Blood Adv. 2020 Feb 25;4(4):676-686. doi: 10.1182/bloodadvances.2019000952.
2
Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Transplant Cell Ther. 2024 Jan;30(1):77.e1-77.e15. doi: 10.1016/j.jtct.2023.10.017. Epub 2023 Oct 27.
3
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
Transplant Cell Ther. 2023 Jun;29(6):349.e1-349.e8. doi: 10.1016/j.jtct.2023.02.021. Epub 2023 Mar 5.
4
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma.
J Hematol Oncol. 2024 Aug 6;17(1):61. doi: 10.1186/s13045-024-01579-w.
5
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
Transplant Cell Ther. 2022 Oct;28(10):669-676. doi: 10.1016/j.jtct.2022.07.011. Epub 2022 Jul 16.
6
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.
Blood Adv. 2021 Sep 14;5(17):3397-3406. doi: 10.1182/bloodadvances.2020003885.
7
Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Radiology. 2022 Feb;302(2):438-445. doi: 10.1148/radiol.2021210760. Epub 2021 Nov 9.
8
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.
Blood Adv. 2020 Apr 14;4(7):1432-1439. doi: 10.1182/bloodadvances.2019001304.
9
Dermatologic Adverse Events Associated With Chimeric Antigen Receptor T-Cell Therapy: A Pharmacovigilance Analysis of the FDA Reporting System.
Transplant Cell Ther. 2024 Oct;30(10):1035.e1-1035.e7. doi: 10.1016/j.jtct.2024.06.024. Epub 2024 Jun 28.
10
Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Ann Pharmacother. 2021 Mar;55(3):390-405. doi: 10.1177/1060028020944233. Epub 2020 Jul 22.
引用本文的文献
1
CAR T-Cell Therapy in Cancer: Balancing Efficacy with Cardiac Toxicity Concerns.
J Cancer Sci Clin Ther. 2025;9(3):140-153. Epub 2025 Sep 8.
2
Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.
Am J Cancer Res. 2025 Aug 15;15(8):3417-3433. doi: 10.62347/GJNN1023. eCollection 2025.
3
ITK overexpression enhances T cell cytotoxicity against DLBCL through the TCR-Ca-Calcineurin-NFAT-IFN-γ pathway.
Sci Rep. 2025 Aug 21;15(1):30789. doi: 10.1038/s41598-025-16112-3.
4
Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.
Blood Adv. 2025 Nov 11;9(21):5489-5500. doi: 10.1182/bloodadvances.2025016149.
5
Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus study.
EClinicalMedicine. 2025 May 28;84:103256. doi: 10.1016/j.eclinm.2025.103256. eCollection 2025 Jun.
6
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma.
Transplant Cell Ther. 2025 Jul;31(7):419-433. doi: 10.1016/j.jtct.2025.03.011. Epub 2025 Apr 25.
7
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.
Nat Med. 2025 Apr;31(4):1183-1194. doi: 10.1038/s41591-025-03532-x. Epub 2025 Apr 1.
8
Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience.
Curr Oncol. 2025 Mar 17;32(3):173. doi: 10.3390/curroncol32030173.
9
Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.
Haematologica. 2025 Jun 1;110(6):1254-1268. doi: 10.3324/haematol.2024.286027. Epub 2025 Feb 20.
10
Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies.
Blood Adv. 2025 Apr 8;9(7):1644-1657. doi: 10.1182/bloodadvances.2024015157.
本文引用的文献
1
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Biol Blood Marrow Transplant. 2019 Dec;25(12):2305-2321. doi: 10.1016/j.bbmt.2019.08.015. Epub 2019 Aug 22.
2
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).
Bone Marrow Transplant. 2019 Nov;54(11):1868-1880. doi: 10.1038/s41409-019-0451-2. Epub 2019 May 15.
3
Management of Immunotherapy-Related Toxicities, Version 1.2019.
J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013.
4
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
5
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Blood Rev. 2019 Mar;34:45-55. doi: 10.1016/j.blre.2018.11.002. Epub 2018 Nov 14.
6
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
7
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
8
Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.
J Hematol Oncol. 2018 Jun 13;11(1):81. doi: 10.1186/s13045-018-0627-z.
9
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Cancer Discov. 2018 Aug;8(8):958-971. doi: 10.1158/2159-8290.CD-17-1319. Epub 2018 Jun 7.
10
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.
Zotero 插件